{"id":8012,"date":"2023-12-05T12:44:15","date_gmt":"2023-12-05T12:44:15","guid":{"rendered":"https:\/\/dailyai.com\/?p=8012"},"modified":"2023-12-05T12:48:06","modified_gmt":"2023-12-05T12:48:06","slug":"astrazeneca-bets-247m-on-ai-company-developing-cancer-drug","status":"publish","type":"post","link":"https:\/\/dailyai.com\/fr\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","title":{"rendered":"AstraZeneca mise $247millions d'euros sur une soci\u00e9t\u00e9 d'IA d\u00e9veloppant un m\u00e9dicament contre le cancer"},"content":{"rendered":"<p><strong>AstraZeneca s'est engag\u00e9e \u00e0 verser $247 millions d'euros pour financer les efforts de la soci\u00e9t\u00e9 Absci, sp\u00e9cialis\u00e9e dans la d\u00e9couverte de m\u00e9dicaments issus de l'IA, en vue de mettre au point un anticorps contre le cancer.<\/strong><\/p>\n<p>Absci utilise son syst\u00e8me g\u00e9n\u00e9ratif <a href=\"https:\/\/dailyai.com\/fr\/2023\/07\/ai-accelerates-discovery-of-anti-aging-drugs-in-new-study\/\">D\u00e9couverte de m\u00e9dicaments par l'IA<\/a> pour d\u00e9couvrir de nouveaux m\u00e9dicaments potentiels et les valider ensuite dans ses laboratoires humides.<\/p>\n<p>Avec ce projet soutenu par AstraZeneca, Absci tentera de cr\u00e9er un anticorps qui se lie \u00e0 une cible oncologique sp\u00e9cifique. La soci\u00e9t\u00e9 n'a pas encore r\u00e9v\u00e9l\u00e9 quel type de cancer elle vise avec ce projet.<\/p>\n<p>Les anticorps constituent une perspective int\u00e9ressante pour <a href=\"https:\/\/dailyai.com\/fr\/2023\/06\/researchers-build-breakthrough-ai-model-for-drug-discovery\/\">nouveaux m\u00e9dicaments<\/a> parce qu'ils sont tr\u00e8s s\u00e9lectifs dans les cibles auxquelles ils se lient et qu'ils ont des effets immunog\u00e8nes minimes. Cependant, il est difficile de trouver un nouvel anticorps aux propri\u00e9t\u00e9s sp\u00e9cifiques qui soit facile \u00e0 fabriquer.<\/p>\n<p>Le nombre de combinaisons de prot\u00e9ines possibles pour fabriquer diff\u00e9rents anticorps est pratiquement illimit\u00e9. Trouver un anticorps qui fasse ce que l'on veut, c'est donc faire preuve de discernement et de t\u00e2tonnements.<\/p>\n<p>La recherche traditionnelle d'anticorps est donc tr\u00e8s gourmande en temps et en ressources. Il s'agit de cribler de grandes biblioth\u00e8ques immunitaires ou synth\u00e9tiques pour trouver des anticorps candidats potentiels. Ces candidats doivent ensuite \u00eatre synth\u00e9tis\u00e9s avant de confirmer qu'ils se lient de mani\u00e8re optimale \u00e0 la cible.<\/p>\n<p>La plateforme de cr\u00e9ation int\u00e9gr\u00e9e de m\u00e9dicaments d'Absci utilise des mod\u00e8les d'apprentissage automatique form\u00e9s sur des essais en laboratoire, ou des proc\u00e9dures exp\u00e9rimentales, g\u00e9n\u00e9rant des milliards de donn\u00e9es d'interaction prot\u00e9ine-prot\u00e9ine.<\/p>\n<p>Le mod\u00e8le d'IA apprend les principes d'ing\u00e9nierie sous-jacents qui permettent aux diff\u00e9rentes prot\u00e9ines de se comporter comme elles le font. La plateforme utilise son moteur d'IA g\u00e9n\u00e9ratif pour cr\u00e9er des anticorps synth\u00e9tiques de novo, c'est-\u00e0-dire \u00e0 partir de z\u00e9ro, dans une approche z\u00e9ro-coup.<\/p>\n<p>Pour les anticorps, l'approche \"zero-shot\" signifie que les prot\u00e9ines candidates g\u00e9n\u00e9r\u00e9es par l'IA sont bas\u00e9es sur des principes premiers, plut\u00f4t que sur des donn\u00e9es historiques d'autres prot\u00e9ines connues pour se lier \u00e0 un agent pathog\u00e8ne sp\u00e9cifique.<\/p>\n<p>L'utilisation de l'IA permet de d\u00e9terminer plus rapidement et plus pr\u00e9cis\u00e9ment les prot\u00e9ines qui m\u00e9ritent d'\u00eatre \u00e9tudi\u00e9es que l'approche humaine qui consiste \u00e0 faire du sur place.<\/p>\n<p>Les prot\u00e9ines candidates sont ensuite valid\u00e9es exp\u00e9rimentalement dans les laboratoires d'Absci. La plateforme de conception de prot\u00e9ines par l'IA acc\u00e9l\u00e8re la d\u00e9couverte de m\u00e9dicaments en achevant le cycle de collecte de donn\u00e9es, de conception par l'IA et de validation en laboratoire humide en six semaines environ.<\/p>\n<p>Sean McClain, PDG d'Absci, a d\u00e9clar\u00e9 \u00e0 propos du partenariat avec AstraZeneca : \"AstraZeneca est un leader dans le d\u00e9veloppement de nouveaux traitements en oncologie, et nous sommes ravis de collaborer avec eux pour concevoir un anticorps th\u00e9rapeutique candidat susceptible d'am\u00e9liorer la vie des patients atteints de cancer\"<\/p>\n<p>L'engagement financier d'AstraZeneca dans ce projet est un signe prometteur qui montre que l'entreprise est optimiste quant \u00e0 son potentiel de r\u00e9ussite. L'utilisation de l'IA pour acc\u00e9l\u00e9rer le d\u00e9veloppement des <a href=\"https:\/\/dailyai.com\/fr\/2023\/08\/ai-powered-blood-test-detects-cancers-in-single-dna-molecules\/\">cancer<\/a> auront un impact important sur la vie des patients, ainsi que sur les finances des grandes soci\u00e9t\u00e9s pharmaceutiques.<\/p>","protected":false},"excerpt":{"rendered":"<p>AstraZeneca a engag\u00e9 $247 millions pour financer les efforts de la soci\u00e9t\u00e9 Absci, sp\u00e9cialis\u00e9e dans la d\u00e9couverte de m\u00e9dicaments par l'IA, en vue de mettre au point un anticorps contre le cancer. Absci utilise sa plateforme g\u00e9n\u00e9rative de d\u00e9couverte de m\u00e9dicaments par l'IA pour d\u00e9couvrir de nouveaux m\u00e9dicaments potentiels, qu'elle valide ensuite dans ses laboratoires. Dans le cadre du projet soutenu par AstraZeneca, Absci tentera de cr\u00e9er un anticorps qui se lie \u00e0 une cible oncologique sp\u00e9cifique. La soci\u00e9t\u00e9 n'a pas encore r\u00e9v\u00e9l\u00e9 le type de cancer vis\u00e9 par ce projet. Les anticorps constituent une perspective int\u00e9ressante pour les nouveaux m\u00e9dicaments, car ils sont tr\u00e8s s\u00e9lectifs dans les cibles auxquelles ils se lient et n'ont que peu d'effets immunog\u00e8nes. Cependant, la recherche d'un<\/p>","protected":false},"author":6,"featured_media":8014,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84],"tags":[150,203,107],"class_list":["post-8012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-ai-benefits","tag-biotech","tag-generative-ai"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca bets $247m on AI company developing cancer drug | DailyAI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dailyai.com\/fr\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dailyai.com\/fr\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"DailyAI\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-05T12:44:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-05T12:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Eugene van der Watt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:site\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eugene van der Watt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"author\":{\"name\":\"Eugene van der Watt\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\"},\"headline\":\"AstraZeneca bets $247m on AI company developing cancer drug\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"wordCount\":434,\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"keywords\":[\"AI benefits\",\"Biotech\",\"Generative AI\"],\"articleSection\":[\"Industry\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"width\":1000,\"height\":501},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dailyai.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"name\":\"DailyAI\",\"description\":\"Your Daily Dose of AI News\",\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dailyai.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\",\"name\":\"DailyAI\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"width\":4501,\"height\":934,\"caption\":\"DailyAI\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/DailyAIOfficial\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/dailyaiofficial\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@DailyAIOfficial\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\",\"name\":\"Eugene van der Watt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"caption\":\"Eugene van der Watt\"},\"description\":\"Eugene comes from an electronic engineering background and loves all things tech. When he takes a break from consuming AI news you'll find him at the snooker table.\",\"sameAs\":[\"www.linkedin.com\\\/in\\\/eugene-van-der-watt-16828119\"],\"url\":\"https:\\\/\\\/dailyai.com\\\/fr\\\/author\\\/eugene\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca mise $247m sur une soci\u00e9t\u00e9 d'IA d\u00e9veloppant un m\u00e9dicament contre le cancer | DailyAI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dailyai.com\/fr\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_locale":"fr_FR","og_type":"article","og_title":"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI","og_description":"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an","og_url":"https:\/\/dailyai.com\/fr\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_site_name":"DailyAI","article_published_time":"2023-12-05T12:44:15+00:00","article_modified_time":"2023-12-05T12:48:06+00:00","og_image":[{"width":1000,"height":501,"url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","type":"image\/jpeg"}],"author":"Eugene van der Watt","twitter_card":"summary_large_image","twitter_creator":"@DailyAIOfficial","twitter_site":"@DailyAIOfficial","twitter_misc":{"\u00c9crit par":"Eugene van der Watt","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#article","isPartOf":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"author":{"name":"Eugene van der Watt","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa"},"headline":"AstraZeneca bets $247m on AI company developing cancer drug","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"wordCount":434,"publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","keywords":["AI benefits","Biotech","Generative AI"],"articleSection":["Industry"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","url":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","name":"AstraZeneca mise $247m sur une soci\u00e9t\u00e9 d'IA d\u00e9veloppant un m\u00e9dicament contre le cancer | DailyAI","isPartOf":{"@id":"https:\/\/dailyai.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","breadcrumb":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","width":1000,"height":501},{"@type":"BreadcrumbList","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dailyai.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca bets $247m on AI company developing cancer drug"}]},{"@type":"WebSite","@id":"https:\/\/dailyai.com\/#website","url":"https:\/\/dailyai.com\/","name":"DailyAI","description":"Votre dose quotidienne de nouvelles sur l'IA","publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dailyai.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/dailyai.com\/#organization","name":"DailyAI","url":"https:\/\/dailyai.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","width":4501,"height":934,"caption":"DailyAI"},"image":{"@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/DailyAIOfficial","https:\/\/www.linkedin.com\/company\/dailyaiofficial\/","https:\/\/www.youtube.com\/@DailyAIOfficial"]},{"@type":"Person","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa","name":"Eug\u00e8ne van der Watt","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","caption":"Eugene van der Watt"},"description":"Eugene a une formation d'ing\u00e9nieur en \u00e9lectronique et adore tout ce qui touche \u00e0 la technologie. Lorsqu'il fait une pause dans sa consommation d'informations sur l'IA, vous le trouverez \u00e0 la table de snooker.","sameAs":["www.linkedin.com\/in\/eugene-van-der-watt-16828119"],"url":"https:\/\/dailyai.com\/fr\/author\/eugene\/"}]}},"_links":{"self":[{"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/posts\/8012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/comments?post=8012"}],"version-history":[{"count":5,"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/posts\/8012\/revisions"}],"predecessor-version":[{"id":8018,"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/posts\/8012\/revisions\/8018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/media\/8014"}],"wp:attachment":[{"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/media?parent=8012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/categories?post=8012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailyai.com\/fr\/wp-json\/wp\/v2\/tags?post=8012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}